YD Bio

YD Bio EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of YD Bio (YDES) as of Oct 16, 2026 is -63.31. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was -107.78 — a change of -41.26% (higher).

EV/FCF

-63.31

YoY

-41.26%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of YD Bio is 2025 -63.31 . EV/FCF (Enterprise Value to Free Cash Flow) of YD Bio was 2024 -107.78 . It decreases by -41.26% higher compared to the previous year.

The YD Bio EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2020
-2,027.03 USD
Jan 1, 2021
-747.81 USD
Jan 1, 2022
-170.31 USD
Jan 1, 2023
-9,201.04 USD
Jan 1, 2024
-107.78 USD
Jan 1, 2025
-63.31 USD
The YD Bio EV/FCF history
YEAREV/FCFYoY
-63.31-41.26%
-107.78-98.83%
-9,201.04+5,302.58%
-170.31-77.23%
-747.81-63.11%
-2,027.03—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

YD Bio Stock analysis

What does YD Bio do? YD Bio Ltd is a company based in Taipei City, Taiwan, with its headquarters located in Taipei City. The company is set to go public on August 29, 2025, under the ticker symbol YDES and ISIN KYG983011076. YD Bio Ltd focuses on developing innovative solutions in the healthcare sector, particularly in early cancer detection and next-generation cell therapies. The company's core activities include creating non-invasive cancer detection tools for early diagnosis and monitoring, as well as developing ophthalmologic products for dry eye conditions. Additionally, YD Bio Ltd is engaged in exosome-based therapeutics designed to address complex diseases. The company aims to enhance patient outcomes and quality of life through the integration of advanced scientific research with practical, accessible healthcare solutions. YD Bio Ltd operates within the healthcare industry, though specific sector and industry classifications are not provided. The company's website is http://ir.ydesgroup.com/, where further information about its operations and future plans can be found. As a Taiwan-based entity, YD Bio Ltd contributes to the biotechnology and medical innovation landscape in the region. The company's IPO date is scheduled for 2025, indicating its readiness to expand its market presence and potentially scale its operations. YD Bio Ltd's mission centers on pioneering transformative healthcare solutions that improve and extend patient lives. YD Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about YD Bio stock

EV/FCF (Enterprise Value to Free Cash Flow) of YD Bio is -63.31 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of YD Bio changed from -107.78 to -63.31, representing a -41.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) YD Bio since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s YD Bio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — YD Bio

All Key Metrics — YD Bio